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Edited by Veli-Pekka LehtoAbstract We have recently established that the blood concen-
trations of gallic acid (GA), a polyphenolic component naturally
found in food, and its O-methyl derivatives are very low
(practically < 1 lM) in physiological (postprandial) condition.
Using acellular oxidant systems and macrophage-diﬀerentiated
promonocytes (MDPs) THP-1, we show here that the direct and
indirect (through depressing eﬀect on the superoxide cell
production) antioxidant properties of these components were
not eﬀective at these concentrations. In contrast, 4-O-methyl GA
was the most eﬃcient component to depress AT1R and CD36
mRNA expression in Ang II-treated MDPs, suggesting a strong
inhibition of Ang II-triggered pro-atherogenic mechanisms of
foam cell formation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ﬁrst stages of atherosclerosis leading to the formation of
the lipid core (atheroma) imply endothelial cells, macrophage-
diﬀerentiated monocytes and vascular smooth muscle cells
(VSMC) of the vessel wall [1]. All these cell types are able to
release bioactive substances, in particular reactive oxygen
species (ROS) and cytokines, which play a crucial role in the
pathogenesis [2]. It is worthwhile to notice that the production
of a ROS, the superoxide anion (O2 ), and the O

2 -generating
oxidase subunit expression are increased by several cytokines
[3–5] resulting in the oxidized LDL (oxLDL) formation,
whereas oxLDL is able to in turn stimulate O2 production
[6,7] and oxLDL receptor CD36 expression [8], leading to lipid* Corresponding author. Fax: +33-4-67-66-08-71.
E-mail address: leger@univ-montp1.fr (C.L. Leger).
Abbreviations: AAPH, 2-20-azobis-(2-amidinopropane)-hydrochloride;
Ang II, angiotensin II; AT1R, Ang II type 1 receptor; CD, conjugated
dienes; GA, gallic acid; 3-OMGA and 4-OMGA, 3-O-methyl gallic
acid and 4-O-methyl gallic acid; MDP, macrophage-diﬀerentiated
promonocyte; PMA, phorbol-12-myristate-13-acetate; PP, polyphe-
nols; RDI, retinoic acid, vitamin D3, interferon c; SIN-1, 3-morpho-
linosydnonimine
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doi:10.1016/j.febslet.2004.10.015accumulation and foam cell formation [9]. This could be
considered as a self-ampliﬁcation loop in which O2 -generating
process and CD36 expression interfere.
Hypertension has long been considered as an atherogenic
risk factor. The occurrence of a mechanistic link between hy-
pertension and atherosclerosis is now established through the
pleiotropic action of angiotensin II (Ang II) [10], the main
peptide eﬀector of the renin–angiotensin system. In addition to
the vaso-constrictory action, Ang II is an inﬂammatory,
chemoattractant, cell-growth and diﬀerentiation-promoting
agent [11,12], and its production has been attested in the vas-
cular wall [12,13], highlighting its pivotal role in atherogenesis.
Ang II synthesis by macrophage-diﬀerentiated promonocyte
(MDP) cells THP-1 has also been established [14]. Ang II ac-
tion is mainly mediated by a cell-surface receptor, the Ang II
type 1 receptor (AT1R) [15].
CD36, a class B scavenger receptor with multifunctional
properties, is found in endothelial cells, monocytes/macro-
phages (and promonocyte cell line THP-1), VSMC, adipocytes
and (cardio)myocytes. One of its functions is to recognize
(minimally) oxLDL. Its activation leads to atherogenic and
inﬂammatory processes [16]. It is abundantly represented in
the core of the atherogenic plaque and generally considered
atherogenic as strongly suggested by the CD36 null mice
outcome [17]. It mediates enhanced H2O2 production in
macrophages [18] (known to result predominantly from O2 -
release) and its proper enhanced expression once activated by
oxLDL [19].
Little is known on the role of Ang II in monocytes/macro-
phages. There is indirect evidence for an Ang II-induced in-
crease in the respiratory burst and the oxidant stress [20–22]. It
has been recently shown that Ang II-injected mice exhibited an
increased expression of CD36 mRNA compared to non-in-
jected mice [21].
Polyphenols (PP) – and particularly gallic acid (GA) –
are antioxidant in vitro and protect other antioxidants in
the biological ﬂuids and LDL [23–26] in vivo. GA is found
in plants and beverages in the free or bound forms [27]. 4-
O-Methyl gallic acid (4-OMGA) has ﬁrst been identiﬁed as
a major methyl derivative of GA in human plasma and
urine [28]. More recently, 4-OMGA and 3-O-methyl gallic
acid (3-OMGA) have been found in urine during regular
black tea ingestion [29] and in plasma after moderate red
wine consumption [30].blished by Elsevier B.V. All rights reserved.
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GA, 3-OMGA and 4-OMGA at protecting LDL against in
vitro generated oxidative modiﬁcations, with a special refer-
ence to their physiological concentrations [30], and second to
compare these antioxidant capacities to their cell-modulating
action in Ang II-treated, diﬀerentiated THP-1, with a special
reference to their action on O2 -production, on the one hand,
and AT1R and CD36 mRNA expression, on the other.2. Materials and methods
2.1. Materials
Gallic acid, angiotensin II, phorbol-12-myristate-13-acetate (PMA),
10,100-dimethyl-9,90-bisacridinium dinitrate (lucigenin), INFc, and
retinoic acid were purchased from Sigma–Aldrich (Saint Quentin
Fallavier, France), 2-20-azobis-(2-amidinopropane)-hydrochloride
(AAPH) was from Biovalley (Conches, France), 3-morpholinosyd-
nonimine (SIN-1) was from Interchim (Montlucon, France). Stan-
dards of the O-methyl ether forms (3-OMGA and 4-OMGA) of GA
were prepared from GA methyl ester according to Raju et al. [31]. Cell
culture medium and fetal calf serum (FCS) were from Bio Media
(France). 1a,25-dihydroxycholecalciferol was a gift from Hoﬀmann-La
Roche SA (Basel, Switzerland). The ATP bioluminescent reagent
(Vialight HS kit) was obtained from Cambrex Ltd (France). RNeasy
mini extraction kit was from Qiagen (Courtaboeuf, France). Hybond
N-nylon membrane was obtained from Amersham Biosciences Europe
(Orsay, France).
2.2. Preparation, biochemical parameters and oxidizability of LDL
Human plasma was collected from normo-lipidemic patients un-
dergoing plasmapheresis sessions in the Hematology Department of
Hospital Lapeyronie (Montpellier, France). Preparation and determi-
nation of biochemical parameters of LDL were carried out as previ-
ously described [32,33]. LDL oxidation was performed at conventional
(diluted) concentration already used [23,33] or at near physiological
(more concentrated) concentration (6 0.1 and 1 lMLDL, respectively,
expressed as apo B) after a preincubation time period. For oxidation at
conventional concentration, LDL (1 lM) was preincubated for 1 h at
37 C under N2 in the presence of products to be tested, and oxidized
either by 5 lM Cu2þ after 10-fold dilution in PBS, or by 2.5 mM
AAPH after 20-fold dilution, or by 21 lM SIN-1 after 10-fold dilution
in PBS containing 10 lM DTPA. For oxidation at near physiological
concentration, LDL was preincubated as above and oxidized without
dilution in the presence of either 100 lM Cu2þ or 5 mM AAPH or 230
lM SIN-1. These concentrations were justiﬁed by the need to keep on
a high oxidant/LDL molar ratio in order to obtain the same kinetics of
oxidation – i.e., of conjugated diene (CD) production – as in the
conventional condition [34]. LDL oxidizability was assessed by mea-
suring the CD produced with monitoring at 234 nm in the case of Cu2þ
and SIN-1 and at 245 nm in the case of AAPH [33]. Oxidation lag time
was assessed for Cu2þ and AAPH, whereas CD production was di-
rectly measured for SIN-1. Respective mechanisms of action of the
three oxidation systems have already been compared [33]. Brieﬂy, the
Cu2þ-oxidation system leads to Cu2þ interaction with an LDL low-
aﬃnity binding site (in the present condition of at least 50/1 Cu/LDL
molar ratio) [34], then to the reduced form Cuþ which in turn leads to
lipid peroxide formation. AAPH is able to directly produce radicals in
the aqueous phase and thus to trigger lipid peroxidation independently
of transition metals. The SIN-1, ONOO-generating system corre-
sponds to a di-electronic process, in which ONOO formation results
from the simultaneous release of nitric oxide and superoxide by the
3-morpholinosydnonimine molecule, and the subsequent immediate
reaction between them. This mimicks their simultaneous massive
productions occurring particularly in the endothelial dysfunction
involved in atherogenic processes.2.3. Cell line and culture
The human THP-1 cell line was a gift from Dr. J. Dornan (Uni-
versity of Montpellier). Cells were maintained in culture and diﬀer-
entiated as previously described [33]. Brieﬂy, for diﬀerentiation into
adherent macrophages, promonocytes were plated in 96-well micro-plates (2.5 105cell/well of 0.2 ml) or seeded into a T-75 culture ﬂask
for 72 h in the presence of 1 lM retinoic acid, 0.1 lM vitamin D3 and
100 U/ml IFNc (the RDI mixture). This diﬀerentiating mixture was
used instead of PMA in order to avoid the downregulating cell eﬀect of
prolonged PMA-incubation time on PKC and PKC-dependent events
(including superoxide production) [35]. Then, the culture medium was
replaced by the same one without the diﬀerentiating agents and MDPs
were incubated further at 37 C for 24 h with the substances to be
tested. MDPs (100 ll) were incubated in the presence of 0.08% trypan
blue for 5 min, and colored (dead) cells were observed under light
microscope. The percentage of viable cells was superior to 95%.
2.4. Superoxide anion production assessment
The production of O2 by MDPs was measured at 37 C with luci-
genin-ampliﬁed chemiluminescence (104M lucigenin) by means of a
microplate luminometer (EGG Berthold, France). MDPs were placed
in the RPMI medium and incubated with Ang II for 24 h, in the
presence or absence of PP. Finally, the medium was changed and PMA
(0.1 lM) was added. The luminescence signal was counted over the 90-
min period following PMA addition. In the control conditions, RPMI
medium only contained the solvent vehicle used for PP dilution (eth-
anol, not exceeding 0.2% in the medium). The cell number was then
determined by using a commercial kit for ATP extraction and deter-
mination. Brieﬂy, this assay consists in the ﬁreﬂy luciferase-catalyzed
oxidation of D-luciferin in the presence of ATP and oxygen, providing
a direct relationship between ATP and the light produced. Results
were expressed as the total amount of the O2 -generated luminescence
per mol of ATP.
2.5. RNA isolation and Northern blot analysis
Total RNA was prepared from THP-1 cells using RNeasy mini ex-
traction kit. Once diﬀerentiated and co-incubated in the presence of
Ang II and PP to be tested, culture medium was aspirated, cells were
washed twice with cold PBS (pH 7.4) and scraped. Cell suspension was
then centrifuged (10 min, 2000 rpm) and submitted to RNA extraction.
Total RNA (20 lg) was separated by 2% agarose/formaldehyde gel
electrophoresis and transferred to a Hybond N-nylon membrane in
0.05 M NaOH. Northern blots were prehybridized for 1 h at 42 C in
the hybridization buﬀer and then hybridized overnight with a random-
primed, [a-32P]dCTP-labeled, CD36 or AT1R cDNA probe. Speciﬁc
mRNA expression was quantiﬁed by means of a Fujix BAS1000
PhosphorImager. The mRNA for GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) was used to normalize gene expression. cDNA
was obtained by RT-PCR of total RNA (1 lg) and then used as a
template for subsequent PCR. 50-ATGTAACCCAGGACGCTGAG
and 50-AAGGCCTTGGATGGAAGAAC were used as sense and
antisense oligonucleotides, respectively, in the case of CD36 primers
and 50-CTGGGGCTGCATTGTATTCT and 50-AAACCAGTGTG-
GACCAGGAG as sense and antisense oligonucleotides, respectively,
in the case of AT1R primers. The PCR products were puriﬁed and
quantiﬁed on a 1% agarose gel electrophoresis.
2.6. Statistics
ANOVA and non-paired Student’s t test were used for statististical
analyses. Results were given as means S.D.3. Results
Fig. 1 shows the IC50 values obtained for GA, 3-OMGA and
4-OMGA at conventional LDL concentration (Fig. 1A) and at
near physiological LDL concentration (Fig. 1B). It appears
clearly that in conventional condition, 4-OMGA was practi-
cally without protective eﬀect or the less antioxidant form
towards the three oxidation systems, whereas 3-OMGA was
the most potent of the three forms, with the most protective
eﬀect exerted in the presence of the SIN-1 oxidation system.
Interestingly, the results in Fig. 1B were diﬀerent from those in
Fig. 1A, since in the more physiological condition the most
protective eﬀect was found with 3-OMGA in the presence of
the Cu2þ oxidation system. Taken together, Figs. 1A and B
Fig. 1. Antioxidant capacities of the three forms of GA expressed as
the concentration needed for a decreased LDL oxidizability by 50%
(IC50). For expression of the antioxidant capacities with the Cu
2þ- and
AAPH-oxidation systems, the lag time (Tlag) of LDL oxidation due to
PP was ﬁrst measured and compared to the Tlag without PP, leading to
calculate a relative Tlag (rTlag) [33], then the logarithm of 1/rTlag, which
is plotted vs increasing PP concentrations, allowing to assess the IC50
value. For SIN-1-oxidation system, IC50 were obtained by a direct
plotting of the molar ratio CD-production/apoB-concentration vs in-
creasing PP concentrations. (A) Oxidation at conventional concen-
tration (LDL 6 0.1 lM). (B) Oxidation at near physiological
concentration (1-lM LDL).
Fig. 2. Superoxide production in 72-h diﬀerentiated MDPs. (A) Eﬀect
of Ang II on the PMA-stimulated O2 -production. Cells were incu-
bated with Ang II for 24 h, PMA (0.1 lM) was then added for a time
period (90 min) during which the lucigenin-chemiluminescence was
measured. Data were from seven separate experiments. (B) Eﬀect of
gallic acid on the O2 -production in the 0.1-lM Ang II-treated MDPs.
Data were from four separate experiments. In A and B, the values for
each experiment corresponded to the means of three determinations.
P < 0:05 vs control.
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sessing antioxidant capacity were of prime importance. In
addition, it is worth comparing the IC50 values of the three
forms obtained in the more physiological condition to their
actual concentrations in plasma as reported by labels in
Fig. 1B. We found that neither GA nor 4-OMGA had IC50
values compatible with an antioxidant eﬀect in plasma re-
gardless of the oxidation system. In contrast, the IC50 value of
3-OMGA was low enough (0.24 lM) to be protective towards
Cu2þ oxidation at circulating concentration in plasma (0.25
lM).
In PMA-stimulated MDPs, an increase in O2 -production
was observed with the diﬀerentiation time. The highest pro-
duction was found for 72-h diﬀerentiation (not shown). We
chose this diﬀerentiation time for all the experiments. After an
additional 24-h incubation time with increasing Ang II con-
centrations, the PMA-stimulated MDPs showed (Fig. 2A) an
O2 -production which culminated at 0.1 lM, corresponding to
a 35% increase when compared to the no Ang II-treated
MDPs. We next examined whether PP exhibit modulating ef-
fects on the O2 -production of Ang II-treated, PMA-stimu-
lated MDPs. Fig. 2B clearly showed that growing
concentrations of GA (in a concentration range of 0.012 lM to
2 lM) were able to increasingly inhibit O2 -production. The
inhibition peak value (near 50%) reached a plateau for 1–2 lM
GA. It is worth noticing that 0.25 lM GA had no signiﬁcanteﬀect. Interestingly, no inhibition was found with 3-OMGA
and 4-OMGA at any concentration (not shown).
Fig. 3A shows that the expression peak of CD36 mRNA was
obtained after a 72-h diﬀerentiation time, with an expression
increasing by 67% as compared to non-diﬀerentiated cells.
Therefore, the following experiments were carried out on 72-h
diﬀerentiated MDPs. In one case, we added PMA in condi-
tions which were similar to those used for superoxide pro-
duction, i.e., at the concentration of 0.1 lM and with an
incubation time of 90 min (Fig. 3B). This resulted in a CD36
mRNA expression even more pronounced. On the other hand,
incubating Ang II for 24 h dose-dependently increased the
CD36 mRNA expression (Fig. 4). In our hand, the highest
expression was obtained for 0.1 lM Ang II. This action
appeared to be similar to that of 0.1 lM PMA. As illus-
trated by Fig. 5, GA, 3-OMGA and 4-OMGA were able to
Fig. 4. Ang II enhances CD36 mRNA expression in MDPs. After a 72-
h diﬀerentiation time, cells were incubated with increasing doses of
Ang II for 24 h. Data (means S.D.) were given for three separate
experiments. P < 0:05 vs control.
Fig. 3. Relationship between CD36 mRNA expression and diﬀerenti-
ation time of THP-1. Cells were diﬀerentiated by retinoic acid, IFNc
and vitamin D3 for 48, 72 or 96 h. After total RNA isolation, the
expression of CD36 mRNA was analyzed by Northern blot at each
time point. Its expression was normalized by GAPDH mRNA ex-
pression. Data (means S.D.) were given for three separate experi-
ments. (A) CD36 mRNA expression as a function of time. (B) In 72-h
diﬀerentiated MDPs, an additional 90-min incubation with 0.1-lM
PMA led to increase the CD36 mRNA expression. P < 0:01 vs non-
diﬀerentiated THP-1. Fig. 5. Eﬀects of the three forms of gallic acid on the CD36 mRNA-
expression in MDPs. Cells were treated with Ang II (0.1 lM) in the
presence or absence of GA, 3-OMGA or 4-OMGA. Total RNA was
isolated, Northern blot analysis for CD36 mRNA was quantiﬁed by
means of a PhosphorImager and normalized by GAPDH mRNA.
Data (meansS.D.) were given for three separate experiments.
P < 0:05; P < 0:01 vs control (in the absence of PP, but in the
presence of Ang II and solvent vehicle).
242 M.V.B. Oliveira et al. / FEBS Letters 577 (2004) 239–244dose-dependently inhibit the expression of CD36 mRNA. A
47%, 65% and 82% inhibition of CD36 mRNA expression was
obtained for 1 lMGA, 3-OMGA, and 4-OMGA, respectively.
In the same condition of PP concentration, the inhibition of
AT1R mRNA expression was of 34%, 38% and 84%, respec-
tively (Fig. 6).4. Discussion
We have recently showed that the circulating concentrations
of GA and their O-methyl derivatives in blood do not exceed
0.25 lM for GA and 3-OMGA, and 1.1 lM for the 4-OMGA
(Fig. 1B) after drinking a moderate volume (300 ml) of red
wine [30]. It will be of interest to compare these concentration
values to those revealing a biological action.
We show here that the biological properties of GA metab-
olites presently studied were diﬀerent and they were also dif-
ferent from those of GA. This was true for the direct
antioxidant properties, for the regulation of superoxide pro-duction and for the mRNA expression involved in foam cell
formation (CD36 mRNA, in particular) in MDPs.
Considering the circulating concentrations of GA and GA
derivatives, it is shown that physiological concentrations were
not able to signiﬁcantly prevent LDL oxidation in the two in
vitro oxidation systems (AAPH and SIN-1) considered to be
relevant from a pathophysiological viewpoint (see [33] for
discussion of this point). This does not mean, however, that
these polyphenolic compounds are totally devoid of antioxi-
dant properties. Likewise, physiological concentrations of GA
were not able to signiﬁcantly impair the superoxide cell pro-
duction (Fig. 2A), whereas 3-OMGA and 4-OMGA did not
exhibit any regulatory action at any concentration tested.
Fig. 6. Eﬀects of the three forms of GA on the AT1R mRNA ex-
pression in MDPs. Cells were treated with Ang II (0.1 lM) in the
presence or absence of GA, 3-OMGA or 4-OMGA at a concentration
of 1 lM. For other information, see Fig. 5. P < 0:05; P < 0:01 vs
Ang II only.
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ineﬀective antioxidants at physiological concentrations in the
presence of cell-released superoxide, which is the most suitable
approach to assess both the direct radical-scavenging and the
released-radical impairing due to PP [36].
In contrast, physiological concentrations of 4-OMGA – and
to a lesser extent those of GA and 3-OMGA – were able to
considerably depress the CD36 and AT1R mRNA expression
in MDPs. In fact, we show for the ﬁrst time that Ang II en-
hanced the expression of these two mRNAs in THP-1-derived
macrophages and that 4-OMGA was not only able to coun-
teract this action of Ang II, but also to decrease the mRNA
expression beyond the one observed without Ang II, suggest-
ing that the mechanism of action of this PP is not purely re-
stricted to its role as modulator of AT1R mRNA expression.
The 4-OMGA property presently found by us is of particular
interest, especially as (i) the renin–angiotensin system is up-
regulated during THP-1 diﬀerentiation [14] and (ii) Ang II is
known to exhibit a promigratory action on THP-1 monocytes
[37], which contributes to its proatherogenicity. On the other
hand, these results also showed that Ang II may not only in-
crease CD36 expression by promoting oxLDL formation [8]
through the increased superoxide production [11], but also
directly interfere with the regulatory pathways involved in
macrophage CD36 expression.
Altogether, these ﬁndings strongly suggest that the biologi-
cal properties presently found are not explained by the direct
antioxidant properties of GA and its O-methyl derivatives.
Indeed, the less active form as antioxidant, 4-OMGA, was the
most active towards the decrease in the CD36 and AT1R
mRNA expressions.
Generally speaking, and regardless of the concentration
conditions, 3-OMGA was the most antioxidant form of GA.
The antioxidant capacity of GA was, however, close to that of3-OMGA with both the Cu2þ and SIN-1 oxidation systems.
This is in accordance with their highly antioxidant ortho-
diphenol structure which, in contrast, is disrupted in 4-
OMGA. However, the very low antioxidant capacity of GA
with the AAPH oxidation system remains to be explained. In
contrast, the discrepant results of Fig. 1A and B – obtained in
conventional (non-physiological) and more physiological
conditions of concentration, respectively – underline the need
for a critical examination of the conditions generally used for
assessing antioxidant protection of LDL.
In VSMC, Ang II signaling has been shown to depend on
the PKC/MAPK-mediated expression of AT1R via an AP-1
element (probably c-Fos) regulation [38,39]. The present re-
sults obtained in a model of macrophage could be explained
partly by the GA potency to depress AP-1 activity [40]. There
is also a possibility that PKC activity was impaired by GA as
suggested by the phenolic-acid impairing of PKC-dependent
superoxide production already found by our group [36].
However, the Ang II action is also mediated by the Rho-
protein/Rho-kinase/NFjB pathway [41] and by a tyrosine
kinase pathway [42], on which PP eﬀects remain to be thor-
oughly explored. On the other hand, considering the Ang II
capacity at mediating the oxLDL uptake, the present results
show that this bioactive peptide is able to enhance expression
of LOX-1 [43,44] and CD36 as well – as presently suggested
by the increased expression of its mRNA – both known as
oxLDL receptors.
It is worth noting that PMA-stimulated superoxide pro-
duction was potentiated by pre-incubating MDPs with Ang II.
The same is true for the increased CD36 mRNA expression due
to incubating MDPs with PMA once cells were diﬀerentiated
with the diﬀerentiating mixture (Fig. 3B). These results provide
evidence that PMA kept on its stimulating and diﬀerentiating
properties in the present conditions of diﬀerentiation (using the
RDI mixture). It is indeed well known that prolonged cell-
incubation with PMA (generally for 12 h) usually employed
for cell diﬀerentiation leads to PMA-insensitive THP-1 cells
[45].
Interestingly, 4-OMGA was found to be the most potent
form to depress AT1R and CD36 mRNA expression. Blocking
the AT1R pathway by a pharmacological approach through
the angiotensin converting enzyme inhibition as carried out in
ramipril-receiving mice has been shown to result in impairing
CD36 mRNA expression in macrophages [46]. Using another
approach, we found here a similar result.
In conclusion, among the three forms of GA presently
studied, the 4-O-methyl derivative of GA appears to be the
most potentially eﬀective one in preventing Ang II-triggered
foam cell formation. Its mechanism of action may imply de-
pressing eﬀects on both AT1R and CD36 mRNA expressions.
Further studies on the corresponding-protein expression and
on animal model are needed to conﬁrm the anti-atherogenic
eﬀect of GA metabolites and to provide clear mechanistic ev-
idence for an atheroma-formation preventing role of a PP-rich
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